Download or read book 2nd International Adalat Symposium written by Wilhelm Lochner and published by Springer. This book was released on 2013-12-11 with total page 385 pages. Available in PDF, EPUB and Kindle. Book excerpt: The First Adalat Symposium held in Tokyo in 1973, presented important experimental and clinical results which had been collected in Europe and Japan with the new coronary therapeutic agent. The European scientists had an opportunity to discuss the problems and results personally with their Japanese colleagues. The Second Adalat Symposium was held in Amsterdam within a year with the purpose of bringing together mainly scientists within Europe. The results discussed in Tokyo have been extended and supplemented through additional experiences. Contributions in basic science are presented, but most important are those clinical studies, which support and extend proof of the drug's efficacy in humans. The editors wish to express their appreciation to all those responsible for contributing to this report and, in particular, to Dr. M. SPENGLER, Dr. F. EBNER and Dr. K. BRANDAU for their editorial help, and to Dr. W. BOTTGER for the preparation of the Subject Index. We hope that this publication will be a valuable contribution toward conveying information to physicians and scientists. DiisseldorfjWuppertal, Autumn 1975 W. LOCHNER' W BRAASCH' G. KRONEBERG Contents Introduction: W. LOCHNER Present Basis of Coronary Therapy: W. LOCHNER. With 11 Figures 2 Session I. Chemistry and Experimental Pharmacology (Chairmen: A. FLECKENSTEIN and K. LANDMARK) Pharmacology of Nifedipine: G. KRONEBERG. With 8 Figures 12 Discussion Remarks 19 The Chemistry of Nifedipine: F. BOSSERT. With 9 Figures 20 Pharmacokinetics of Adalat in Animal Experiments: K. PATZSCHKE, B.
Download or read book Pharmacology of Antihypertensive Therapeutics written by Detlev Ganten and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 922 pages. Available in PDF, EPUB and Kindle. Book excerpt: The previous volume on Antihypertensive Agents in the Handbook of Experi mental Pharmacology, published in 1977, was edited by the late Franz Gross from the Department of Pharmacology in Heidelberg, who was one of the grand old men in hypertension research. Now, more than 10 years later, it is necessary to update this volume. From the early days of antihypertensive drug treatment, starting about 30 years ago with drugs such as reserpine and guanethidine, the pharmacology of cardiovas" cular therapy has evolved into a highly sophisticated and effective therapeutic regimen. The major breakthroughs in the 1960s were the introduction of diuretics and beta-blockers. Then, in the 1980s, came the calcium antagonists and con verting enzyme inhibitors. It can be anticipated that the next decade will see a further expansion and sophistication of blood pressure lowering drugs. This book provides a state-of-the-art discussion of chemical, experimental, and clinical pharmacological data as well as of practical experience with drugs which are presently being used or which are going to be introduced on the market in the near future. The purpose of this volume is to provide a complete discussion of antihypertensive agents. Each major class of antihypertensive drugs is treated exhaustively in a separate chapter, fully referenced with chemical formulae, and richly illustrated with figures and tables. International authorities were asked to contribute in their respective fields of expertise.
Download or read book Calcium Antagonists written by Helmut Lydtin and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 414 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume critically and objectively analyses the literature up to 1989 and presents a guide to the practical use of all calcium antagonists which have been thoroughly investigated to date. It begins with a concise review of physiological principles as a basis for a discussion of the general and specific pharmacodynamics and pharmacokinetics of calcium antagonists. Special emphasis is given to their therapeutic use in practice, precise dosage schedules are provided, interactions with other medications described, and therapeutic alternatives considered.
Download or read book Cardiovascular Effects of Dihydropyridine Type Calcium Antagonists and Agonists written by A. Fleckenstein and published by Springer Science & Business Media. This book was released on 2013-03-12 with total page 520 pages. Available in PDF, EPUB and Kindle. Book excerpt: Held at Boppard, Germany, October 3-6, 1984
Download or read book Current Catalog written by National Library of Medicine (U.S.) and published by . This book was released on 1993 with total page 1628 pages. Available in PDF, EPUB and Kindle. Book excerpt: First multi-year cumulation covers six years: 1965-70.
Download or read book National Library of Medicine Current Catalog written by National Library of Medicine (U.S.) and published by . This book was released on with total page 1028 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders written by Peter H. Stone and published by Blackwell/Futura. This book was released on 1983 with total page 520 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Receptors and Centrally Acting Drugs Pharmacokinetics and Drug Metabolism written by E. S. Vizi and published by Elsevier. This book was released on 2013-10-22 with total page 529 pages. Available in PDF, EPUB and Kindle. Book excerpt: Advances in Pharmacological Research and Practice, Volume 2: Receptors and Centrally Acting Drugs presents the proceeding of the 4th Congress of the Hungarian Pharmacological Society, held in Budapest, Hungary in 1985. This book presents a comprehensive view of the developments in the fields of receptors and centrally acting drugs as well as in pharmacokinetics and drug metabolism. Organized into two sections encompassing 25 chapters, this volume begins with an overview of prejunctional regulation of neuromuscular transmission. This text then explores the whole-body autoradiography that is used extensively in toxicological research and screening. Other chapters consider the three major classes of models used in pharmacokinetics. This book discusses as well the various aspects of melanin–drug interactions. The final chapter deals with the investigation on the melanin affinity of amphetamine derivatives. This book is a valuable resource for pharmacologists, pharmacokineticists, and researchers.
Download or read book Clinical Pharmacology of Antianginal Drugs written by U. Abshagen and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 562 pages. Available in PDF, EPUB and Kindle. Book excerpt: When I was asked some years ago by the editors of the Handbook of Experimental Pharmacology to edit a new volume on Antianginal Drugs, I agreed on the condition that, in accordance with my scientific background, primary emphasis be given to clinical pharmacology and therapeutics. It soon turned out that, due to rapid developments in this field, nothing of the previous volume on Antianginal Drugs by Charlier (Vol. 31, 1971) could be retained apart from its basic idea of devoting considerable space to methodology. Since editors must operate within certain limits, I had to abstain from dealing with acute myocardial infarction in detail despite the well-known overlap between unstable angina, the preinfarction syndrome, and acute myocardial infarction. It was only possible for acute myocardial infarction and the concept of reduction of infarct size to be briefly discussed within the chapter on pathophysiology of acute coronary insufficiency. The chapter on invasive methods provided an opportunity to touch on new approaches to early intervention in acute myocardial infarction. Here, intracoronary streptokinase therapy and PTCA are considered, again with attention to the overlap between mechanical and pharmacological interventions.
Download or read book Robotics written by United States. Congress. House. Committee on Science and Technology. Subcommittee on Investigations and Oversight and published by . This book was released on 1982 with total page 1314 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book 2nd International Adalat r Symposium written by W Lochner and published by . This book was released on 1975-12-01 with total page 392 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Pharmaceutical Innovation promises and Problems written by United States. Congress. House. Committee on Science and Technology. Subcommittee on Natural Resources, Agriculture Research, and Environment and published by . This book was released on 1982 with total page 260 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Profiles of Drug Substances Excipients and Related Methodology written by and published by Academic Press. This book was released on 1990-01-23 with total page 657 pages. Available in PDF, EPUB and Kindle. Book excerpt: Profiles of Drug Substances, Excipients and Related Methodology
Download or read book National Union Catalog written by and published by . This book was released on 1973 with total page 616 pages. Available in PDF, EPUB and Kindle. Book excerpt: Includes entries for maps and atlases.
Download or read book Adalat written by P.R. Lichtlen and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 249 pages. Available in PDF, EPUB and Kindle. Book excerpt: As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge.
Download or read book Drugs in the Management of Heart Disease written by A. Breckenridge and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 301 pages. Available in PDF, EPUB and Kindle. Book excerpt: In any textbook, basic scientific knowledge, and the art of clinical practice should be brought together in a rational manner and this volume on cardio vascular therapy attempts to achieve this aim. It deals with five selected areas - hypertension, angina and coronary artery disease, heart failure and anticoa gulant therapy. Clearly not all branches of cardiovascular therapeutics could be included; a separate section on anti-arrhythmic drugs is noticeably absent but it is proposed that this omission will be rectified in other volumes in the series. In general, textbooks on therapeutics tend to be ephemeral; as new discoveries are made and evaluated, medical practice changes. This volume then summarizes current opinion up to mid 1984 and gives, we believe, a reasoned account of present views. The contributors are all clinical pharma cologists with a wealth of clinical experience. The therapeutic advice given is well founded and the underlying scientific basis is clearly explained. The book is aimed at postgraduates, but should the undergraduate care to dip into it, we hope he will be informed and thereby educated. A. Breckenridge vii Series Editor's Note The last few decades have seen an explosion in our knowledge of cardiovas cular disease as a result of research in many disciplines. The tempo of research is ever increasing, so that it is becoming more and more difficult for one person to encompass the whole spectrum of the advances taking place on many fronts.
Download or read book Glaucoma Medical Therapy Principles and Management written by Peter A. Netland Siegal Professor of Opthalmology and Director of Glaucoma University of Tennessee Health Science Center and published by Oxford University Press, USA. This book was released on 2007-11-16 with total page 314 pages. Available in PDF, EPUB and Kindle. Book excerpt: Glaucoma medical therapy has evolved with the advent of each new drug. This evolution has moved quickly and generated new information that clinicians need to understand, synthesize, and implement about medications that have specific benefits and risks for their glaucoma patients. This book aims to provide clinicians with an accessible guide to the current art and science of using clinically available drugs for the medical therapy of glaucoma. The contributors have attempted to present evidence-based information, while providing perspective from their clinical experience. In order to reflect the extensive changes that have occurred since the publication of the first edition in 1999, new chapters have been added about fixed combination drugs and the medical treatment of pediatric patients, and existing chapters have been thoroughly revised and updated. Glaucoma Medical Therapy will be a valuable reference for ophthalmologists in both practice and training, as well as for other practitioners who have clinical contact with glaucoma patients.
